UCB and Biogen Idec discontinue Phase II clinical trial of CDP323>
UCB and Biogen Idec discontinue Phase II clinical trial of CDP323
(Thomson Reuters ONE) - Preliminary interim efficacy analysis showed no clinically relevantbenefit for patientsBrussels (Belgium), 30 June 2009 at 10:30 pm CEST - press release,regulated information - UCB and Biogen Idec announced today thediscontinuation of the Phase II clinical trial of CDP323 for thetreatment of relapsing multiple sclerosis (MS). Preliminary interimefficacy analysis showed that patients enrolled in this clinicaltrial did not benefit as expected from CDP323 compared to placeboafter a six month treatment period. No cases of PML (progressivemultifocal leukoencephalopathy) were noted.CDP323 is an oral small molecule alpha4 integrin inhibitor that wasbeing developed by UCB and Biogen Idec for relapsing forms ofmultiple sclerosis.For UCB, results of this interim analysis trigger a re-valuation ofthe intangible asset "CDP323". UCB expects a non-cash, non-recurringimpairment of a high double-digit million pre-tax euro amount. Thiswill be more than compensated by cash, non-recurring capital gains,which resulted from the divestitures UCB made earlier this year. Moreinformation on the financial impacts of both the impairment and thecapital gains will be included in the Half Year Report 2009 of UCB,due July 31, 2009.Further informationAntje Witte, Corporate Communications & Investor Relations, UCBT +32.2.559.9414, antje.witte(at)ucb.comMichael Tuck-Sherman, Investor Relations, UCBT +32.2.559.9712, Michael.tuck-sherman(at)ucb.comNancy Nackaerts, External Communications, UCBT +32.2.559.9264, nancy.nackaerts(at)ucb.comEimear O'Brien, Global CNS Communications Manager, UCBT +32.2.559.9271, Eimear.OBrien(at)ucb.comShannon Altimari, Public Affairs, Biogen IdecT:+1 617-914-6524, Shannon.Altimari(at)biogenidec.comJohn Applegate, Investor Relations, Biogen IdecT: +1 617-679-2812, John.Applegate(at)biogenidec.comNotes to the EditorsAbout Multiple SclerosisMultiple sclerosis (MS) is a chronic disease of the central nervoussystem that affects an estimated 1.1 - 2.5 million people worldwide.Although the exact cause is unknown, MS occurs as a result of loss ofthe protective outer coating on nerves in the brain and spinal cord.Deterioration in the way that messages are transmitted around thebody leads to loss of movement and other body functions. Symptoms ofMS can include vision problems, loss of balance, numbness, difficultywalking and paralysis.About Biogen IdecBiogen Idec creates new standards of care in therapeutic areas withhigh unmet medical needs. Founded in 1978, Biogen Idec is a globalleader in the discovery, development, manufacturing, andcommercialization of innovative therapies. Patients in more than 90countries benefit from Biogen Idec's significant products thataddress diseases such as lymphoma, multiple sclerosis, and rheumatoidarthritis. For product labeling, press releases and additionalinformation about the company, please visit www.biogenidec.com.About UCBUCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical companydedicated to the research, development and commercialization ofinnovative medicines with a focus on the fields of central nervoussystem and immunology disorders. Employing around 10 000 people inover 40 countries, UCB produced revenue of 3.6 billion euro in 2008.UCB is listed on Euronext Brussels (symbol: UCB).Forward looking statementThis press release contains forward-looking statements based oncurrent plans, estimates and beliefs of management. Such statementsare subject to risks and uncertainties that may cause actual resultsto be materially different from those that may be implied by suchforward-looking statements contained in this press release. Importantfactors that could result in such differences include: changes ingeneral economic, business and competitive conditions, effects offuture judicial decisions, changes in regulation, exchange ratefluctuations and hiring and retention of its employees.For the pdf-version of this press release, please click on the linkbelow:http://hugin.info/133973/R/1326231/312091.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Production- and Sales Report for Q2, 2009>
">
" alt="Investor Presentations>
">Datum: 30.06.2009 - 16:30 Uhr
Sprache: Deutsch
News-ID 1002320
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 338 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"UCB and Biogen Idec discontinue Phase II clinical trial of CDP323>
"
steht unter der journalistisch-redaktionellen Verantwortung von
UCB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
